Wetherby probiotics developer agrees five-year Mexican deal
Biotech innovator ProBiotix Health has agreed a five-year commercial partnership allowing a Mexican company exclusive use of one of its patented products.
LPLDL® is a naturally-occurring probiotic which has been proven to have a positive impact on HDL cholesterol and blood pressure, among other things.
The deal will see Mexico-based Raff use LPLDL® as an ingredient for the local manufacturing of finished products. The launch is planned for the first half of 2025, with commercial sales expected in late 2025/early 2026. It also specialises in the use and application of lactic and probiotic cultures, rennet, enzymes and preservatives.
Steen Andersen, CEO of Wetherby-based ProBiotix, said: “After lengthy discussions we are delighted to announce our partnership with Raff and firmly believe that they share our ethos – to develop innovative products to help enrich individuals with healthier lives.
“The cardiovascular drug market in Mexico is estimated to be worth $2.2bn this year, and provides a huge latent opportunity. With an ageing population, we believe Mexico provides a highly attractive market for ProBiotix to target.”
Mexico has a population of 131 million people, with cardiovascular disease the single largest killer, accounting for nearly 24% of all deaths. Moreover, it is estimated that around 3.6 million people die in Mexico every year from high cholesterol. The movement from ‘cure’ towards ‘prevention’ provides a strong backdrop for the fast-growing supplement market, which should lead to a good sales opportunity for ProBiotix.
Rafael Gonzalez, Commercial Director of Raff, added: “As an already well established probiotics supplier in the Mexican market through our relationship with Italy based Sacco Systems, having the opportunity to partner with ProBiotix Health, being a pioneer within probiotics and cardiometabolic health, is extremely exciting for us.
“We welcome the opportunity to expand our portfolio with a unique well documented precision biotic like LPLDL®. It is our belief that LPLDL® fills an untapped potential in the fast growing Mexican supplement market, and that the product sits well with our already strong position in the sector.”
